Dr. Wiechert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Kirstein 3
Boston, MA 02215Phone+1 617-667-4040Fax+1 617-667-4747
Summary
- I am a Gynecologic Oncologist practicing at Beth Israel Deaconess Medical Center in Boston. I am interested in the comprehensive treatment of patients with gynecologic malignancies, including both surgical and medical therapies. I am particularly interested in minimally invasive surgical techniques and biological therapies for Gynecologic cancers. I am also experienced and interested in HIPEC.
Education & Training
- Cleveland Clinic FoundationFellowship, Gynecologic Oncology, 2014 - 2017
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Obstetrics and Gynecology, 2010 - 2014
- University of Pittsburgh School of MedicineClass of 2010
Certifications & Licensure
- MA State Medical License 2017 - 2025
- NH State Medical License 2018 - 2022
- OH State Medical License 2014 - 2017
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Special Resident in Minimally Invasive Gynecology AAGL, 2014
Publications & Presentations
PubMed
- 19 citationsThy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.Elizabeth V. Connor, Caner Saygin, C. Braley, Andrew Wiechert, Sheelarani Karunanithi
Journal of Ovarian Research. 2019-11-17 - 62 citationsCx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase.Praveena S. Thiagarajan, Maksim Sinyuk, Soumya M. Turaga, Erin E. Mulkearns-Hubert, James S. Hale
Nature Communications. 2018-02-08 - 58 citationsCD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.Caner Saygin, Andrew Wiechert, Vinay S. Rao, Ravi Kumar Alluri, Elizabeth V. Connor
The Journal of Experimental Medicine. 2017-09-04
Professional Memberships
- Member
- Society of Gynecologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: